Baker Bros. Advisors Reduces $46M in Immunocore Holdings plc ($IMCR)
Key Points
- Baker Bros. Advisors changed its Immunocore Holdings plc ($IMCR) stake by 68.4% last quarter, cutting to 734,397 shares worth $21.27 million.
- Wall Street's consensus rating on $IMCR is Buy and an average price target of $63.49.
- $IMCR last traded around $28.96.
Baker Bros. Advisors reduced its position in Immunocore Holdings plc ($IMCR) by 68.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 734,397 shares of Immunocore Holdings plc after selling 1,588,259 shares during the quarter. Baker Bros. Advisors's holdings in Immunocore Holdings plc were worth $21.27 million as of its most recent filing.
Immunocore Holdings plc ($IMCR) Stock
Immunocore Holdings plc Earnings
Analysts Set New Price Targets
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.